DURHAM, N.C.--(BUSINESS WIRE)--Argos Therapeutics today announced the presentation of two abstracts related to its Arcelis™ HIV immunotherapy program at the 18th Annual Canadian Conference on HIV/AIDS Research, held in Vancouver April 23-25th, 2009. These abstracts, presented by Argos’ collaborators at McGill University Health Centre, detail research validating the feasibility and safety of the AGS-004 immunotherapy candidate for HIV, as well as the apheresis collection procedure used to generate the immunotherapy product. AGS-004 is a personalized immunotherapy, generated by the Arcelis platform, which consists of patient-specific, monocyte-derived dendritic cells and RNA encoding autologous HIV antigens, and is perfectly matched to each patient’s unique viral burden.
